Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone

Arcturus Therapeutics Holdings Inc.

ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.
LUNAR-FLU program achieves $17.5M development milestone from CSL Seqirus; funds used for flu program development activities.
The factory will support cGMP production of mRNA drug substance and drug product for Arcturus' STARR mRNA vaccines.
CSL Seqirus is exclusive global licensee for mRNA vaccines against COVID-19, flu, and three other respiratory diseases.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. entered into CSL Collaboration Agreement with Seqirus, Inc., a part of CSL Seqirus (effective 2022-12-08).

Action: entry
Agreement: collaboration
Counterparty: Seqirus, Inc., a part of CSL Seqirus
Effective: 2022-12-08

Exact text from the filing

the Company entered into the CSL Collaboration Agreement with CSL Seqirus for the global exclusive rights to research, develop, manufacture and commercialize Arcturus’ self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases with nonexclusive rights to pandemic pathogens

View on SEC.gov

Browse all material agreements →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-001174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.